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Animal models of serious infection suggest that 24 hours of induced hypothermia improves circulatory and respiratory 
characteristics, and reduces mortality. We tested the hypothesis that reducing core temperature to 32-34
o
C attenuates 
organ dysfunction and reduces mortality in ventilator-dependent patients with septic shock.  
METHODS  
In this parallel group, open-label, randomized controlled trial, patients were enrolled within six hours after onset of 
septic shock with respiratory failure from participating intensive care units. They were randomized 1:1, to routine 
thermal management or 24 hours of induced hypothermia (target 32-34°C) followed by 48 hours of normothermia. 
Other aspects of care were per routine. Patients and care givers were not blinded to the treatment allocation; the 
assessors of the primary outcome were blinded to the treatment allocation. The primary endpoint was 30-day all-cause 
mortality. Clinicaltrials.gov number: NCT01455116. 
FINDINGS 
The CASS trial recruited patients from November 1
st
 2011 to November 4
th
 2016. At the 3rd scheduled interim 
analysis, after recruitment of 432 of the planned 560 participants, the Monitoring Board recommended that the trial be 
terminated for futility. The hypothermic target temperature was reached in a median of 3·2 hours [Interquartile range 
(IQR): 2·2, 4·8]. In the hypothermia group, 96/217, 44·2% died within 30 days vs. 77/215, 35·8% in the routine 
thermal management group, (absolute difference 8·4 percentage points; 95% CI -0·8 to 17·6; relative risk 1·24 [95% 
CI: 0·98, 1·56, p=0·074]). At 72 hours after inclusion, 165/191 (86·4%) were still on mechanical ventilation in the 
hypothermia group vs. 144/192 (75·0%), absolute difference 11·4 percentage points; 95% CI 3·1 to 18·9, p=0·0071; 
132/191 (69·1%) vs. 102/192 (53·1%) still received vasoactive medication, absolute difference 15·9 percentage 
points; 95% CI 6·8 to 26·4, p=0·0019.   
INTERPRETATION 
Among patients with septic shock and ventilator-dependent respiratory failure, induced hypothermia did not reduce 
mortality, and instead prolonged the duration of acute respiratory failure and shock.  Induced hypothermia should not 
be used in patients with septic shock.   
FUNDING 




Septic shock is an acute life-threatening condition caused by a deleterious non-resolving host response to  pathogenic 
microorganisms that leads to organ dysfunction .
1
 Key aspects of the pathophysiology include endothelial dysfunction, 
vasodilation, coagulopathy, mitochondrial breakdown, and consequent organ function loss.
2
 Respiratory failure 




Sepsis remains a 
leading cause of death in hospitals
4
, and multiple attempts to improve the prognosis have failed in recent decades. 
5-8
  
In rodents, induced hypothermia for sepsis, in the range of 31-34
o
C maintained for 24-72 hours, has been associated 
with a substantial mortality reduction.
9-11
 The benefit of induced hypothermia appears consequent to reduced sepsis-






 In reptiles, bacteraemia challenge studies have shown that body 
temperatures as high as 42
 o
C were associated with a higher survival rate.
15
 
On a cellular level, improved intracellular metabolism was observed in a pneumococcal challenge model, along with 
reduced dissemination of the infection to other organs in cooled animals.
16
 In rabbits challenged with bacteraemia, 
pyrexia has been associated with improved survival.
17
 Paradoxically, physical cooling to reduce fever in a similar 
experiment improved survival.
18




In humans, pharmaceutical fever prevention does not improve organ function or survival in patients with severe 
infections.
20
 However, in a trial of 200 febrile patients in septic shock, external cooling to normothermia reduced the 
need for vasoactive therapy and non-significantly improved mortality.
21
 Data from a small uncontrolled study of 
induced hypothermia in patients with sepsis and respiratory failure also suggested improved cardiac physiology and 
survival.
22
 Based on animal evidence and limited human data, induced hypothermia has been used as a treatment for 
serious infections for decades
23,24
  — although there is currently no convincing evidence that induced hypothermia 
improves survival in human septic shock. We decided only to recruit patients of 50 years or above for power concerns, 
since we noted a low mortality rate among the younger septic shock patients in a previous trial.
25
 When the 
intervention was designed, several members of the steering committee with experience in this field, mentioned the 
challenge with “rebound” fever after therapeutic hypothermia. This phenomenon was estimated to be rather frequent 
and far from negligible, and the potential harm from severe hyperthermia was considered as a possible limitation in 
the intervention: if some patients would have benefit from the intervention and the same or other patients be harmed 
from rebound fever, the interpretation of the trial results may eventually be compromised. The notion from the 
steering committee was to decide for a two-phased intervention to avoid rebound fever: 24 hours of induced 
 4 
hypothermia followed by 48 hours fever-control/normothermia. During our trial, it has been published that in cardiac 
arrest patients, rebound fever is frequent, approx. 30%-40%.
26,27





C as defined by others.
28
 The question of whether to aim for a hypothermia intervention or a 
fever control (normothermia) intervention was discussed in the steering committee: All members agreed that the 
rationale for induced hypothermia in this patient group was strong, as summarized by others also
29
, and since this 
intervention had never been tested in a trial setting, all members of the steering committee wanted to test this. 
However, the steering committee also agreed that the rationale for testing fever control was present. Some members 
weighted that the effect on intracellular functions seemed to be more pronounced in hypothermia in animal studies. A 
possibility of a three armed trial was discussed (fever respect, fever control, induced hypothermia). However, this 
would increase the needed sample substantially and would not be feasible in the planned setting. We were aware that a 
trial of fever control was already ongoing. In summary, we decided to test the induced hypothermia intervention. 
 
We therefore tested the hypothesis that reducing core temperature to 32-34
o
C for 24 hours followed by slow 
rewarming and normothermia for 48 hours (fever control) attenuates organ dysfunction and reduces mortality in 
patients with septic shock and accompanying acute respiratory failure. Secondary endpoints included duration of 
shock and respiratory failure, alive without need for organ support, inflammation control, and 180-day mortality.  
 
METHODS 
STUDY DESIGN  
The Cooling And Surviving Septic shock study (CASS) was a parallel-group, 1:1, open-label superiority randomized 
trial recruiting patients from ten intensive care units in Europe and North America. For the interim analyses, a group-
sequential design was used. The original and final protocol versions with a complete list of changes (adding of 
additional sites) is available in the supplementary appendix. The protocol was approved by the ethics committees at 
each institution. The steering committee of the trial (see supplementary appendix) vouches for the accuracy and 
completeness of the data and analysis, and that data reporting adheres to the trial protocol.     
The trial was registered at Clinicaltrials.gov: NCT01455116 
 
PARTICIPANTS 
Patients with severe sepsis or septic shock were considered for enrollment when they i) had a mean arterial pressure 
<70 mmHg, ii) were on mechanical ventilation in an intensive care unit (ICU), iii) were ≥50 years, iv) were expected 
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to stay in the ICU for ≥24 hours, and v) could be recruited within six hours after fulfilling all inclusion criteria. 
Exclusion criteria were uncontrolled bleeding, clinically important bleeding disorder (acute or chronic), recent open 
surgery, pregnancy or breast feeding, or involuntary psychiatric admission. Written informed consent was obtained 
from patients or next-of-kin when possible or from two independent medical legal representatives (see supplementary 
appendix), except in the Netherlands and United States where the ethics board required informed consent from 
patients or next-of-kin in all cases. Data management and analysis were performed by Centre of Excellence for Health, 
Immunity and Infections (CHIP), Rigshospitalet, Denmark and University College of London.   
 
RANDOMISATION AND MASKING 
Enrolment, randomization, and data entry were performed via a locally developed online system. Patients were 
randomized 1:1 to induced hypothermia for 24 hours and subsequent normothermia (36·0-38·05
o
C) or to no thermal 
management (control group). Randomization was based on computer-generated variable block sizes stratified for 
validated predictors of mortality, age (≥65 years vs. <65 year), APACHE II score (≥25 vs. <25), and for study site. 
Stratification limits for APACHE II and age were chosen according to the expected medians, this based on a previous 
trial we conducted
25
. The randomization sequence was prepared by the study statistician who did not take part in 
randomization. Allocation was concealed by our web-based system until qualifying patients were consented and ready 
for thermal management.  
Health care professionals taking part in the intervention were aware of the treatment assignment because they were 
responsible for implementing the designated thermal management. However, assessors of the primary endpoint were 
fully blinded to treatment. Investigators and steering committee members were unaware of all data until the trial 
concluded. Since safety of the patients was our primary concern, the Data and Safety Monitoring Board (DSMB), 
which was independent of the steering committee, was unblinded throughout the trial.    
 
PROCEDURES 
In all aspects of treatment, except regarding temperature management, all patients in both groups of the trial, were 
treated according to the most recent surviving sepsis campaign guidelines at the time.
30
  In the control arm, no 
physical or pharmacological thermal interventions were permitted during the initial 24 hours, unless a specific 
indication for hypothermia treatment emerged such as cardiac arrest. Thereafter, antipyretic drugs were allowed as a 
part of the standard treatment.  In patients assigned to hypothermia, the thermal intervention started immediately after 
randomization. The target was to reduce core body temperature to 32-34
o
C within 2 hours. Two types of induced 
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hypothermia intervention were used: 1) external pad-based (n=202 = 93·1%), either using the Artic Sun® device, 
Medivance, Inc., Louiseville, CO, USA, or the Flex.Pads.™ , Emcools, Traiskirchen, Austria or 2) intravenous 
catheter  (n=15 = 6·9%) using the IVTM™, Zoll, Chelmsford, MA, USA) The latter method was used as a “backup” 
method, when other hypothermia devices were used for other purposes at two sites. Mild hypothermia was maintained 
for 24 hours. Thereafter, patients were rewarmed to 37°C at a rate of 0·5°C per hour. And for the next 48 hours, 
patients in the induced hypothermia group were kept normothermic (36-38
o
C) with additional cooling if necessary to 
prevent fever (see supplementary appendix for additional details of thermal management).  
Antibiotics were initiated within an hour after severe sepsis or septic shock was diagnosed, with drug selection based 
on the relevant national guidelines and accounting for differences in distribution and susceptibility of the suspected 
causative microorganisms.  
 
OUTCOMES 
Our primary outcome was 30-day all-cause mortality. Secondary endpoints were defined as: i) all-cause mortality at 
180 days, ii) “days alive and without mechanical ventilation within 30 days”, iii) “days alive and without 
vasopressors/inotropics within 30 days”, iv) “days alive and without dialysis within 30 days”, in the latter three, 
patients who died within 30 days were given the score “0”
31
. v) ICU length of stay (total and separated between 
survivors and non-survivors). Specific organ failures were all assessed at the end of two-phased intervention, at 72 
hours: i) acute respiratory failure: on mechanical ventilation (yes vs. no), ii) PaO2/Fi O2 ratio (median, interquartile 
range (IQR)). Circulatory failure / shock: i) Mean Arterial Pressure (median, IQR), ii) on any vasoactive support (yes 
vs. no), iii) vasoactive-inotropic score (VIS), actual (median, IQR), iv) vasoactive-inotropic score, accumulated 
(median, IQR), v) achieved min. 50% decrease in vasoactive-inotropic score (yes vs. no). VIS was estimated 
according to Gaies et al.
32
 Renal failure: i) diuresis pr. kg pr. hour (median, IQR), ii) creatinine, µmol/L (median, 
IQR), iii) any renal replacement therapy (yes vs. no), iv) acute kidney injury according to RIFLE criteria: R (yes vs. 
no), I (yes vs. no), F (yes vs. no), Any (yes vs. no).
33
 Coagulation: i) International Normalized Ratio (INR, median, 
IQR), ii) platelet count (median, IQR), iii) platelet count<150 x 10
6
/L (yes vs. no), iv) platelet decrease >25% from 
baseline. Liver: i) bilirubin (median, IQR), ii) bilirubin >21 mmol/L. C-reactive protein normalization: i) C-reactive 
protein (median, IQR), ii) CRP decrease>30% from baseline. Cerebral function and sedation: i) receives sedatives (yes 
vs. no), ii) Richmond Agitation Sedation Score (median, IQR), Delirium diagnosed (yes vs. no). Sequential Organ 
Failure Assessment (SOFA) was estimated as defined, except that the data were collected at 06.00 a.m. daily (and not 
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as “worst value last 24 hours”).
34
 Patients discharged from the ICU were considered not to need vasopressor/inotropics 
nor mechanical ventilation.  
 
STATISTICAL ANALYSIS 
Mortality in qualifying patients in the participating centres was estimated to be 40-56%, based on a data draw from 
participating sites, and on the available literature.
35,36
 We thus performed two sample size calculations to cover this 
range of presumed control group event rate: i) Estimated 560 patients would provide 80% power at a two-sided alpha 
level of 0·05 to detect a relative 21% change in the primary endpoint, corresponding to a change in the absolute risk 
from 56% to 44%, ii)This sample size, with equal power and alpha, also allowed us to detect a relative 28% change in 
the primary endpoint, corresponding to a change in the absolute risk from 40% to 29%. No loss to follow up was 
included in the sample-size estimate. 
Since no trials in humans had previously explored hypothermia for severe sepsis or septic shock, safety was a special 
concern, especially the risk of coagulopathy.
37
 Ongoing safety was evaluated at three levels: i) ordinary, full-data 
interim analyses were planned after recruitment of 140, 280, and 420 patients. These included data on the primary 
outcome, on the safety endpoints defined in the protocol, on the intervention (time to target temperature, temperature 
maintenance) and recruitment rates; ii) complications with focus on bleeding and coagulopathy were evaluated after 
the initial 10 and 24 patients were recruited; iii) seven organ-related outcomes were evaluated on a patient-by-patient 
basis by a database manager. The DSMB requested an additional interim analysis at 337 patients, but this evaluation 
was not disclosed to the Steering Committee until after study closure. For the interim analyses, a group-sequential 
design for normally distributed data, based on the approach of O´Brien & Fleming was used.
38
 For the ordinary, full 
data interim analyses, the following terms were employed regarding efficacy and harm: If the z-value for mortality 
analysis was larger than the upper boundary value (efficacy) or smaller than the lower boundary (harm) at the 
specified interim analysis, the trial may be prematurely stopped.  The Z-values used for stopping for efficacy or harm 
at 140, 280 and 420 patients, as displayed in the protocol, were: 3·359, 2·760, 2·359 (efficacy) and -2·241, -2·125, -
2·019 (harm).  
Regarding the planned futility analysis, the following was employed: At 3
rd
 ordinary interim analysis, the DSMB 
formally conducted a futility analysis referring to the protocol. Two distinct assumptions to demonstrate benefit were 
made about unobserved future data: i) that the underlying effect of the intervention was going to remain the same in 
the remaining 140 patients as the rate seen up to stage 6 and ii) that the underlying effect of induced hypothermia was 
as hypothesised when planning the trial. At the actual analysis at 420 patients, the conditional power to demonstrate a 
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benefit from induced hypothermia was effectively zero whatever was assumed about the underlying effect of the 
intervention in the remaining 140 patients. All analyses were done in the modified intention-to-treat population, 
defined as all randomized patients except those in whom the patient or relatives withdrew consent and demanded data 
deleted and those where pre-existing fulfilment of exclusion criteria were discovered after randomization and who 
never received the trial intervention. Patients who had at least one major protocol violation were considered as not 
fulfilling the protocol and additional per-protocol analyses were performed when excluding these patients. A list of 
protocol violations is available in the supplementary appendix.  
All comparisons were between the randomized arms. The primary endpoint was analysed with 1) Kaplan-Meier 
survival curves and corresponding log-rank tests, 2) Cox proportional hazards models, adjusted for pre-stratification 
variables according to published principles for this
39
, 3) subgroup analysis utilizing Cox proportional hazards models 
with interactions tested across stratification layers.  
Secondary endpoints were analysed regarding categorical variables using chi-square for equal proportions (or Fisher´s 
exact test when events were seldom), and continuous outcome measures were compared with Mann-Whitney U-tests 
(non-normally distributed) or Student´s t-test (normally distributed data. All analyses were conducted with R software 
version 3·02 and SAS version 9·4. Tests were two-sided and p values <0·05 were considered statistically significant. 
The corresponding author had full access to all data in the study and had final responsibility for the decision to submit 
for publication.   
 
ROLE OF THE FUNDING SOURCE 
The trial was funded by TrygFonden (App. No. 7-10-1301), Lundbeckfonden (application no. R54-A5342) and Danish 
National Research Foundation [Grant No. DNRF126] (CHIP & PERSIMUNE). Initially, the sites financed the 
cooling equipment. During the trial, C. R. Bard, Inc. (NJ, USA), Emcools, GmbH (Vienna, Austria), and Zoll 
(Chelmsford, MA, USA) agreed to donate cooling equipment. None of the funders had any role in designing the trial, 




The CASS trial recruited patients from November 1
st
 2011 to November 4
th
 2016. At the third scheduled interim 
analysis, the independent Data and Safety Monitoring Board recommended the trial to be closed for futility. At that 
point, 432 of a planned 560 patients had been enrolled and the conditional power for showing a positive effect of the 
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intervention on the primary outcome was zero. The recommendation to close the trial prematurely after the third 
interim analysis was per protocol. Interim analysis data regarding the primary endpoint are available in the 
supplementary appendix. 
A total 220 patients were allocated to receive mild induced hyperthermia and 216 to the control arm.  The next-of-kin 
withdrew consent for three patients. Another patient proved to have a severe bleeding disorder that was considered a 
contraindication to hypothermia. The latter was included in the intention-to-treat analysis (see trial profile, Figure 1).  
The intervention and control groups were fairly balanced at baseline, although acute renal failure seemed more 
frequent in the  mild induced hypothermia group and this group also had a median lower platelet count (table 1). 
Hypothermia was induced in 217 patients. The median time to target temperature was 3·2 hours (IQR 2·2 to 4·7), and 
all but 23 patients reached the target temperature within 6 hours. Twenty-six patients did not complete 24 hours of 
induced hypothermia and 48 hours of normothermia, as detailed in the supplementary appendix. These patients were 
included in the intention-to-treat analysis. Figure 2 shows the temperature in the control and intervention groups 
during the initial 72 hours after randomization. Temperatures differed significantly the treatment groups at all times 
except baseline (P < 0·001) 
 
Follow-up on the primary outcome was complete in all patients. After 30 days, 96/217 patients (44·2%) died in the 
induced hypothermia group compared to 77/215 (35·8%) in the control group (absolute difference 8·4 percentage 
points; 95% CI -0·8 to 18; P = 0·074), relative risk 1·24 [95% CI: 0·98, 1·56] favouring no thermal management, 
figure 3. Patients in the induced hypothermia group, within the first 30 days, had fewer days alive and without 
mechanical ventilation, alive without vasoactive treatment and alive without renal replacement therapy (table 2). The 
duration of critical care was similar in each group (table 2). 
Seventy-two hours after randomization, patients in the induced hypothermia group were more often given vasoactive 
medications: 132/191 (69·1%) vs. 102/192 (53·1%, absolute difference 15·9 percentage points; 6·8 to 26·4; P = 
0·0019). Fewer hypothermic patients had at least 50% reductions in vasoactive medications: 104/187 (55·6%) vs.  
128/184 (69·6%, absolute difference -14·0; 95% CI -23·7 to – 4·2; P = 0·0055). Fewer hypothermic patients had 
>30% decrease in CRP from baseline: 60/180 (33·3%) vs. 88/175 (50·3%, absolute difference -17·0; 95%-CI -27·1 to 
-6·8; p=0·0012 ). More hypothermic patients still required sedation: 150/191 (78·5%) vs. 130/192 (67·7%, absolute 
difference 10·8 percentage points; 95% CI 2·0 to 19·6; p = 0·017). And more hypothermic patients were still 
mechanically ventilated: 165/191 (86·4%) vs. 144/192 (75·0%, absolute difference 11·4 percentage points; 95% CI 
3·1 to 18·9; p = 0·0071), table 2.  
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There were no detectable differences in renal outcome variables. Platelet counts were lower in the induced 
hypothermia arm, but were also lower at baseline. The need for blood transfusions and surgery was similar in each 
group (see supplementary appendix).  
Per protocol, the effects of hypothermia were in pre-planned subgroups, as displayed in figure 4; no subgroup seemed 
to benefit from the intervention. Based on request from the trial Steering Committee, additional exploratory subgroups 
were added: platelets count (≥ 150 x 10
6
/L vs. <150 x 10
6





C). None of the exploratory subgroups of patients had a favourable effect of the intervention 
(negative interaction test), figure 4. Patients with higher eGFR (>60 mL/kg/min), higher platelets (>150 x10
6
/L), 
lower APACHE II score (<25), lower age (<65 years), higher PaO2-ratio (≥20) and female gender non-significantly 
appeared to develop more harm from the intervention (figure 4). Patients cooled with intravenous catheters had similar 




This international randomized trial evaluated patients with sepsis, circulatory failure, and ventilator-dependent 





24 hours, slow rewarming, and 48 subsequent hours of fever suppression was not superior to routine thermal 
management. Specifically, the primary outcome, 30-day all-cause mortality, was not improved by hypothermia — and 
possibly worsened. Furthermore, hypothermia aggravated circulatory collapse, respiratory failure, and delayed the 
decrease in C-reactive protein.   




C based on experimental animal studies showing: i) pronounced 
immunomodulatory effects
40
; ii) reduced sepsis-related liver damage
14,41
 and lung damage
12
; and, iii)  improved 
survival in studies where mammals were cooled to 32-34
o
C (90-93F) for 24-72 hours.
9-11
 In contrast, shorter durations 
of the hypothermia, especially combined with rapid rewarming, appear detrimental.
42
 During the course of the trial, 
additional studies were published showing hypothermia-induced reversion of sepsis-related  mitochondrial 
dysfunction in rats
16
 and marked improvements in respiratory physiology in septic pigs.
12
  
Perhaps the most striking aspect of our negative results is the extent to which they contrast with the positive findings 
in mammals.. Similar divergence in studies of therapeutic hypothermia has been demonstrated in the recent years for 
several clinical entities, including (but not restricted to) :  brain trauma
43,44
 and out-of-hospital cardiac arrest in 
adults,
45
 The most obvious explanation is that hypothermia usually takes several hours to induce in humans by which 
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time tissue damage may already have occurred. Tissue damage consequent to sepsis presumably develops over a far 
longer period than the roughly three hours our patients required to reach the hypothermic target, making sepsis an 
attractive target for therapeutic hypothermia. Since hypothermia was not beneficial, it seems likely that the effects of 
hypothermia on sepsis differ between elderly humans on one hand and young rodents and pigs on the other hand. 
Whether this is a true difference between these animals and humans or rather an age phenomenon remains 
undetermined. 
The most relevant previous human study reported that fever control in patients with septic shock reduced the need for 
vasoactive medications and non-significantly improved mortality (N=200).
21
 Our study combined therapeutic 
hypothermia for 24 hours with fever control from 24 to 72 hours without improving mortality and worsening of other 
outcomes. Thus while fever control appears beneficial in septic patients, the combination of therapeutic hypothermia 
and subsequent fever control is not. A possible explanation for this pronounced difference is suggested to be 
hypothermia-induced tryptophan catabolism and lymphocytopenia, leading to immune paresis.
19,46
  
Since we wanted to explore the effect of induced hypothermia, not fever control, we decided not to restrict the 
inclusion to febrile patients. However, we are aware that febrile patients may be different in many ways, compared to 
normothermic and spontaneously hypothermic patients. To explore whether the effect of the intervention seemed to be 
different in febrile patients compared to others, we did a subgroup analysis and a corresponding interaction test: none 
of these groups seemed to benefit from the intervention.  
We also included patients with spontaneous hypothermia, since the steering committee agreed that spontaneous 
hypothermia is often transient. This has recently been confirmed.
47
  
Two different methods were used for the temperature intervention: external, pad-based or intravenous. The latter was 
used in only few patients as a backup system and the observed mortality in patients cooled with these modalities 
seemed similar and thus, it seems unlikely that different harm profiles from the methods could have driven the harm, 
we noted.  
Pre-defined and post hoc analyses did not identify any subgroups in which hypothermia was especially beneficial or 
harmful, although hypothermia non-significantly caused most harm in the younger, healthier women. This observation 
suggests that potential harm from induced hypothermia may be readily identifiable in those patients, in whom co-
morbidities were not a competing risk for death, reflecting that the signal-to-noise ratio to identify harm was higher in 
this subgroup. Two subgroup analyses showed positive interactions, however none of the subgroups had a significant 
benefit signal, and thus we interpret the positive interactions as a signal that the harm effect was more pronounced 
among certain patient groups, than in others. Since our trial was conducted at ten intensive care units scattered across 
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Europe and North America, the results seem likely to apply broadly. Furthermore, the results were clear: mild 
hypothermia worsened organ function and tended to worsen mortality.  
A limitation of our trial is that investigators and other health care professionals treating the participants were aware of 
the study group allocation; this is an inherent challenge in temperature interventions and other physical interventions. 
However, bias was reduced by using a robust primary endpoint (mortality) assessed by blinded investigators. At one 
site, a surgical intensive care unit, most patients who met other criteria were excluded (before randomization) because 
of recent major surgery; the steering committee nonetheless included this site to enhance accrual and increase 
generalizability. Additionally, we observed a higher use of sedation in the hypothermia group in the intervention 
period, and since substantial harm has been demonstrated from sedation in patients like these
48
, this may, 
independently of the physiological effects of induced hypothermia, have resulted in some harm. And finally, we tested 
a specific amount and duration of hypothermia; results may have differed with other degrees and lengths of 
hypothermia.  
In summary, we did not find a benefit of inducing hypothermia to 32-34
o
C followed by slow rewarming and 48 hours 
of fever prevention in septic patients who required vasopressors and were ventilator-dependent acute lung injury. In 
fact, hypothermia delayed recovery of several key organ functions.Our findings do not support the use of induced 
hypothermia in patients with septic shock. 
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